FDA center directors on lessons from the EUA pathway: Flexibility serves us well
The flexibility of emergency use authorizations, and allowing the FDA to accept more uncertainty during the pandemic so far, has ultimately aided its response to Covid-19, center directors said Tuesday at a workshop at the National Academies of Sciences, Engineering and Medicine.
Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, pointed to the agility of the EUAs, and the ability to quickly revoke any EUAs, as well as the transparency around those decisions as to what led to the evolution of the types of therapeutics that have been authorized (see chart below).
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters